EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

Current Clinical Applications of PSMA-PET for Prostate Cancer Diagnosis, Staging, and Treatment

Franz von Stauffenberg iD, Cédric Poyet, Stephan Beintner-Skawran, Alexander Maurer iD, Florian A Schmid iD

Cancers · 21.12.2024 · 16 (24) · 4263

DOI: 10.3390/cancers16244263 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Cancers, online erschienen am 21.12.2024. Verfasst von Franz von Stauffenberg und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Urology, University Hospital Zurich, University of Zurich, 8091 Zurich, Switzerland. Die Arbeit wurde bisher 44-mal zitiert (Crossref) und nennt 121 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Over the past decade, prostate-specific membrane antigen positron emission tomography (PSMA-PET) has revolutionized prostate cancer (PCa) imaging, offering greater sensitivity and specificity compared to conventional imaging modalities such as CT, MRI, and bone scintigraphy. PSMA-PET is particularly valuable in staging newly diagnosed patients with intermediate- and high-risk disease, detecting biochemical recurrence, and evaluating metastatic cases. By utilizing radiotracers that accumulate specifically in PSMA-expressing cells, even small metastases can be detected, offering a detailed assessment of cancer extent and enabling more targeted diagnostic evaluations. Among the most utilized radiotracers, [68Ga]- and [18F]-labeled PSMA tracers enable precise imaging even with low disease burden. This diagnostic precision also supports advanced therapeutic approaches, including metastasis-directed therapy for oligometastatic cases and systemic treatment options, such as radioligand therapy, which presents new treatment perspectives for metastatic, castration-resistant PCa. This review examines the evolution of PSMA-PET in the diagnostics and therapy of PCa while comparing the current recommendations from leading clinical guidelines. The integration of PSMA-PET into clinical practice has redefined the management of PCa, improving diagnostic accuracy and enabling personalized treatment strategies, while lacking prospective long-term outcome data. As PSMA-PET continues to expand in clinical application, this review highlights its significant advancements while critically addressing limitations to ensure balanced and evidence-based implementation in prostate cancer care.

Schlagwörter

Stichwörter der Autor:innen

PSMA-PETPSMA-RLT[177Lu]Lu-PSMAbiochemical recurrencediagnosismCRPCprostate cancerradical prostatectomyradioligand therapystaging

Autor:innen und Institutionen

  • Department of Urology, University Hospital Zurich, University of Zurich, 8091 Zurich, Switzerland.
  • Department of Urology, Stadtspital Triemli, 8063 Zurich, Switzerland.
  • Department of Nuclear Medicine, University Hospital Zurich, University of Zurich, 8091 Zurich, Switzerland.

ORCID-Profile: Franz von Stauffenberg, Alexander Maurer, Florian A Schmid

Zitieren

APA

von Stauffenberg, F., Poyet, C., Beintner-Skawran, S., Maurer, A., & Schmid, F. A. (2024). Current Clinical Applications of PSMA-PET for Prostate Cancer Diagnosis, Staging, and Treatment. Cancers, 16(24), 4263. https://doi.org/10.3390/cancers16244263

Vancouver

von Stauffenberg F, Poyet C, Beintner-Skawran S, Maurer A, Schmid FA. Current Clinical Applications of PSMA-PET for Prostate Cancer Diagnosis, Staging, and Treatment. Cancers. 2024;16(24):4263. doi:10.3390/cancers16244263

BibTeX
@article{vonStauffenberg2024,
  author = {von Stauffenberg, Franz and Poyet, Cédric and Beintner-Skawran, Stephan and Maurer, Alexander and Schmid, Florian A},
  title = {Current Clinical Applications of PSMA-PET for Prostate Cancer Diagnosis, Staging, and Treatment},
  journal = {Cancers},
  year = {2024},
  volume = {16},
  number = {24},
  pages = {4263},
  doi = {10.3390/cancers16244263}
}
Kostenlos starten →